Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of agrocybe aegerita galactose agglutinin in preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament

A lectin and application technology, which is applied in the field of pharmacological application of poplar mushroom galectin to achieve the effects of inhibiting infection, improving human immunity and reducing viral load

Inactive Publication Date: 2013-01-23
WUHAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no literature report that Populus galectin has pharmacological use against human immunodeficiency virus infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of agrocybe aegerita galactose agglutinin in preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament
  • Application of agrocybe aegerita galactose agglutinin in preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament
  • Application of agrocybe aegerita galactose agglutinin in preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0025] Experimental Example 1 Activity test of fungal lectin AAL against HIV infection

[0026] Anti-HIV experiments include cytotoxicity experiments and anti-HIV replication experiments.

[0027] Cytotoxicity test (MTT assay): C8166 cells (Wuhan Institute of Virology, Chinese Academy of Sciences) were cultured in 96-well plates (3×10 4 / well), C8166 cells were treated with different concentrations (1.25nM, 6.25nM, 30nM, 150nM, 750nM) of fungal lectin AAL (SEQ ID No. 2), each concentration repeated 3 wells, 37°C, 5% CO 2 After 4 days of incubation, cell viability was detected by MTT assay. The concentration of the drug that causes a 50% reduction in cells is CC50.

[0028]HIV Replication Inhibition Assay: In parallel with the cytotoxicity assay, the HIV replication inhibition assay was detected by a p24 antigen capture ELISA assay. C8166 cells were inoculated with HIV-1 LAI (The virus was from the Institute of Virology, Chinese Academy of Sciences), the virus multiplicity ...

experiment example 2

[0032] Experimental Example 2 Experiment on the effect of fungal lectin AAL on virus replication

[0033] HIV-1 infection in C8166 cells LAI Fungal agglutinin AAL (SEQ ID No. 2) was added at different times (0 hours, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, 24 hours) after the virus, and virus replication was detected according to the method in Experimental Example 1. The multiplicity of infection (MOI) of the inoculated virus was 0.05, the final drug concentration was 6.25nM, and the culture system was 300ul. Azidothymidine (AZT) was used as a positive control. The experimental results see figure 2 . The experimental results showed that the inhibitory trend of fungal lectin AAL on the virus was similar to that of AZT, but at the same concentration, the inhibitory effect of fungal lectin AAL on HIV replication was better than that of AZT.

experiment example 3

[0034] Experimental Example 3 The inhibition experiment of fungal lectin AAL on the fusion of chronically infected cells and uninfected cells to form syncytia

[0035] To examine the inhibitory effect of the fungal lectin AAL (SEQ ID No.2) on the formation of syncytia between chronically infected C8166 cells and uninfected C8166 cells, the infected cells were treated with different concentrations of AAL (SEQ ID No.2) (0.2nM, 1nM, 5nM, 25nM, 125nM, 625nM) were incubated for 1 h, washed to remove excess AAL, and then uninfected cells were added to the culture system, wherein the ratio of infected cells to uninfected cells was 1:8. Cells were observed after co-culture for 36 h, and syncytia were counted.

[0036] The experimental results see image 3 . It can be seen from the experimental results that the fungal lectin AAL inhibits the formation of syncytia with an EC50 of 1.73 nM.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of agrocybe aegerita galactose agglutinin to the preparation of an anti-HIV (Human Immunodeficiency Virus) infection medicament. As proved by a large quantity of experiments, a mycoagglutinin ALL (SEQIDNo.2) can effectively suppress the infection of HIV on C8166 cells, can specifically activate the activity of CD4<+>T lymphocytes without influencing CD8<+>T lymphocytes, has high activity on suppressing HIV infestation and stimulating the multiplication of CD4<+>T lymphocytes, can well meet the treatment indexes of reduction in the virus capacity and increase in CD4<+> cells during the treatment of HIV, and can be used for preventing and treating HIV. The invention further discloses an antibody specifically combined with the agrocybe aegerita galactose agglutinin and the application of a nucleotide for coding the agrocybe aegerita galactose agglutinin to the prevention or treatment of HIV infection.

Description

technical field [0001] The present invention relates to a new pharmacological use of fungal lectin, in particular to the pharmacological use of galectin isolated from the fungus Agrocybe aegerita in preventing or treating human immunodeficiency virus (HIV) infection, belonging to Field of pharmacological use of poplar mushroom galectin. Background technique [0002] In the 25 years from the identification of the HIV-1 virus to 2008, approximately 25 million people died of AIDS. According to the statistics of the World Health Organization in 2008, about 33.2 million people in the world are infected with human immunodeficiency virus (HIV), and it is estimated that between 2008 and 2010, 45 million new infections will appear. On February 18, 2009, the Chinese Ministry of Health released a report on the AIDS epidemic. By the end of 2009, there were about 740,000 living HIV carriers and patients in China. In the first three quarters of 2008, 6,897 people died of AIDS in China, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16C07K14/375C12N15/31G01N33/569A61P31/18A61P37/04
Inventor 孙慧李雅木陈义杰姜帅尹亚琳
Owner WUHAN UNIV